STAT
APRIL 5, 2024
The Centers for Disease Control and Prevention urged medical practitioners on Friday to be on the lookout for people who might have contracted H5N1 bird flu from cows. The agency also urged state health departments to rapidly assess any suspected human cases, and recommended that dairy farms with confirmed or suspected outbreaks require workers to use personal protective equipment.
PharmaVoice
APRIL 3, 2024
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ALiEM - Pharm Pearls
APRIL 1, 2024
A 23-year-old female with no known past medical history presented with a rash concentrated on her legs, with a few areas on her arms and chest. The rash began the day before presentation when she became overheated while wearing sweatpants in 104°F weather. The rash was mildly pruritic but not painful. She denied any prior reaction to her sweatpants that she has had for several months.
pharmaphorum
APRIL 2, 2024
Explore the innovative use of artificial intelligence (AI) and machine learning (ML) in securing the pharmaceutical supply chain for resilience and safety. Learn how cutting-edge technology is shaping the future of pharmaceutical logistics.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
STAT
APRIL 5, 2024
News that H5N1 avian influenza has breached another mammalian species — this time dairy cows — has taken the flu science community aback. Though cows previously had been seen to be susceptible to human flu viruses , and could be experimentally infected with H5 in a lab, the absence of cow involvement until now in H5’s nearly 30-year history lulled scientists into thinking the species was outside the virus’s remit.
PharmaVoice
APRIL 1, 2024
Eledon Therapeutics is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
BioPharma Dive
APRIL 1, 2024
The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.
STAT
APRIL 5, 2024
Dogs, our sunny, selfless shadows, crave little more than a daily walk, a treat or two, and their human’s happiness. But increasingly, their own happiness is the topic of concern in veterinarian offices, dog parks, and internet forums. Prozac prescriptions for dogs are on the rise, veterinarians across the country acknowledge, along with a myriad of cheaper generic mood stabilizers sold for humans but applied to pets’ separation anxiety, socialization fears, biting habits, or other
PharmaVoice
APRIL 1, 2024
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.
pharmaphorum
APRIL 4, 2024
Discover how AI-powered real-world evidence generation is revolutionising the biotech industry, providing valuable insights for biopharma companies to make informed decisions. Learn more about the impact of RWD on biotechs.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
APRIL 5, 2024
Hoxa9 and b-catenin molecules are a rare population of self-renewing HSCs found in bone marrow
STAT
APRIL 3, 2024
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, like mental health disorders , Alzheimer’s, and even, as new study results suggest — Parkinson’s disease. In a Phase 2 trial, patients with early Parkinson’s disease taking an older GLP-1 diabetes drug called lixisenatide experienced no worsening of motor symptoms over a year,
PharmaVoice
APRIL 2, 2024
Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VCs like the Dementia Discovery Fund have invested in the next wave of therapies.
pharmaphorum
APRIL 4, 2024
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug class.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Express Pharma
APRIL 1, 2024
In a letter dated March 21, the US FDA India office country director Sarah McMullen said that four states (Gujarat, Telangana, Goa and Karnataka) had been ‘sensitised to FDA’s inspection process and, as such, are eligible for inclusion as observers for relevant inspection in their respective states.’ The letter goes on to mention, ‘We would appreciate relevant opportunities being made available to state inspectors to attend as observers as practical.’ US FDA’s ̵
STAT
APRIL 4, 2024
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease. Relyvrio was approved by the Food and Drug Administration in 2022 , based on data that showed a modest slowing of disease progression. The approval was contentious — regulators initially advised Amylyx not to file for approval until it had conducted another test, but ultimately cleared the drug.
PharmaVoice
APRIL 5, 2024
Infectious diseases that were “off the playing field” are now making a comeback.
pharmaphorum
APRIL 2, 2024
Discover the importance of addressing menopause in the workplace and the benefits of hormone replacement therapy (HRT) through this insightful and informative article on breaking the stigma.
Express Pharma
MARCH 31, 2024
In the dynamic landscape of the pharma industry, collaboration often serves as the key to innovation and expanding market presence. In recent years, the Asia-Pacific (APAC) market has emerged as a hub for pharmaceutical development and investment, attracting attention from both local and global players. While cooperation between APAC-based pharmaceutical companies and their global counterparts has been on the rise, active cooperation among pharma companies within the APAC region is gaining tract
STAT
APRIL 4, 2024
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. Some employees may find positions elsewhere in the company, but they are mostly being pulled from the field.
PharmaVoice
APRIL 4, 2024
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
pharmaphorum
APRIL 2, 2024
In a new episode of the pharmaphorum podcast recorded live on site at WIRED Health in London in March, web editor Nicole Raleigh spoke with Elise de Reus, co-founder of Cradle, the generative AI platform that helps scientists to design and program proteins.
BioPharma Dive
APRIL 5, 2024
The FDA’s clearance comes three weeks after a panel of advisers endorsed expanded use of Abecma despite safety concerns raised by the agency.
STAT
APRIL 1, 2024
Texas health officials reported Monday that an individual who had been in contact with cattle has contracted H5N1 avian flu, only the second case ever recorded in the U.S. The person had contact with dairy cattle that are believed to have been infected with the virus, the Texas Department of State Health Services said in a statement. It went on to say that the individual’s only symptom is eye inflammation — infection of the conjunctiva, the tissue surrounding the eye.
Pharmaceutical Commerce
APRIL 5, 2024
In an interwith with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value and Access Advisor, Schoonveld Advisory, explains why pharmaceutical products tend to cost more in the US than the rest of the world.
pharmaphorum
APRIL 4, 2024
Last week, pharmaphorum editor-in-chief Jonah Comstock travelled to Philadelphia for Reuters Pharma USA. On today’s podcast, he chats with guest host and Deep Dive editor Eloise McLellan about his biggest takeaways from the two-day event.
Pharma Times
APRIL 3, 2024
The third most common and serious form of cancer affects over 43,000 people every year in the UK
STAT
APRIL 1, 2024
Hospitals performing pelvic and other sensitive exams for training purposes without patients’ explicit consent, including on anesthetized patients, won’t be eligible for Medicare and Medicaid reimbursement, according to new guidance released on Monday by the Department of Health and Human Services’ Centers for Medicare and Medicaid Services.
Express Pharma
APRIL 4, 2024
First phase with a builtup area of 29,000 square meters to be completed within a year, second phase by 2026 Gujarat-based SAVA Healthcare conducted the ground-breaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March. This green field project will expand the manufacturing capabilities of SAVA Healthcare as well as create 1000+ job opportunities, offering advanced skill development for the local tale
pharmaphorum
APRIL 4, 2024
Healthcare system Providence has spun out a new company, Praia Health, focused on a platform to build and sustain connections between patients and health providers. The new company starts life with $20 million in Series A funding and a mission to develop the Praia Health Identity and Engagement Platform, which was launched within Providence’s digital innovation group (DIG) incubator in 2022 and already handles around 3.5 million user accounts.
BioPharma Dive
APRIL 3, 2024
The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.
STAT
APRIL 1, 2024
Since the U.S. surgeon general’s 2023 advisory on social media and teen mental health, public concern has skyrocketed around adolescents’ digital lives. Major news organizations and even state governments have pinned social media apps as addictive , dangerous, and the cause of the youth mental health crisis. In turn, calls to ban teens from social media apps have started to emerge, with mixed reception from policymakers nationwide.
Express Pharma
APRIL 4, 2024
The companies will join forces to advance the use of precision medicine on a global scale SOPHiA GENETICS, a cloud-native software company in the healthcare space has announced a strategic partnership with Strand Life Sciences to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and inno
pharmaphorum
APRIL 2, 2024
Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Merz. The announcement made last night US time sparked a run on Acorda's shares, down almost 62% at the time of writing. The news emerged shortly after Acorda cancelled its fourth-quarter results conference call, which was scheduled to take place yesterday.
Expert insights. Personalized for you.
364 
Let's personalize your content